ARISING HEALTHALIVE. AWAKE. AWARE.Read the magazines →

← November 18, 2026 edited reader edition

THE ARISING · Longevity & Healthspan

A small Alzheimer’s trial tests an antibody that changes immune activity

The 40-person safety study found immune-related side effects and did not show that the treatment slows cognitive decline.

Some experimental Alzheimer’s treatments aim at amyloid or tau. IBC-Ab002 takes a different approach: it temporarily blocks PD-L1, part of a system that normally restrains immune activity. Researchers want to know whether changing that activity can help the brain, but the first human trial was designed mainly to learn about safety, not to answer whether patients get better.

The randomized, double-blind phase 1b trial enrolled 40 people with early Alzheimer’s disease across 11 sites. Thirty received the antibody and 10 received placebo. The results, published in Nature Medicine in July, showed that a measure of immune activity in the blood rose after infusion and returned near baseline before the next infusion. That is evidence that the drug affected its intended pathway, not that it changed the course of the disease.

Researchers observed no serious adverse events they attributed to treatment, and no cases of the brain swelling or bleeding seen on scans with some amyloid-targeting antibodies. But 10 of 30 people who received the drug had immune-related side effects, compared with one of 10 on placebo. One participant developed persistent low thyroid function requiring treatment. Another developed a marked liver enzyme elevation without symptoms that later resolved. Three people in the treatment group stopped the drug because of side effects. Forty participants is too few to rule out uncommon or longer-term harms.

Exploratory spinal-fluid tests suggested that some markers of nerve and synapse damage might have fallen at the highest dose. That comparison used paired samples from five people at the highest dose and six people on placebo. None of the marker differences was statistically significant. It is not evidence that patients thought more clearly, functioned better or declined more slowly.

The next meaningful result would come from a larger trial that can measure changes in memory and day-to-day function alongside harms. Until then, the findings support studying the approach further, not using it to treat Alzheimer’s disease.

Read the randomized phase 1b trial in Nature Medicine

THE ARISING NEWSLETTER

Science moves forward.
Come with it.

Research, clear explanations, and a little room for wonder.
Read and follow The Arising on Substack.

Find The Arising on Substack ↗